FDA Grants Priority Review to UGN-101 for Urothelial Cancer
The FDA has granted a priority review designation to a new drug application for UGN-101 for the treatment of patients with low-grade, upper tract urothelial cancer.
Related Articles
Dato-DXd Plus Durvalumab ± Carboplatin Delivers Antitumor Activity in Advanced NSCLC
Frontline treatment with datopotamab deruxtecan plus durvalumab with/without carboplatin proved active in advanced NSCLC without actionable alterations.
China’s NMPA Accepts MAA for Foritinib in ALK+ Advanced NSCLC
China’s NMPA has accepted an MAA seeking the approval of foritinib for ALK-positive advanced non–small cell lung cancer.
Neratinib Generates CNS Responses Across HER2+ Breast Cancer Brain Metastases Subgroups
Neratinib-containing combinations are consistently effective across CNS end points in patients with HER2-positive breast cancer brain metastases.
China’s NMPA Approves Sacituzumab Tirumotecan for Pretreated EGFR+ Advanced NSCLC
The Chinese NMPA has approved sacituzumab tirumotecan for EGFR-mutant advanced NSCLC following progression on an EGFR TKI and chemotherapy.
Novel Index Identifies Social Vulnerability Barriers to Cancer Clinical Trial Enrollment
Lower odds of enrollment in cancer clinical trials could be associated with education, transportation, and neighborhood resources.
Latent Viruses in Human Genome Inspire Novel Directions for Kidney Cancer Immunotherapy
Dana-Farber investigators found that normally defunct viral genes that lie dormant in the human genome can be activated in ccRCC.
Zongertinib Displays Early Activity and Tolerability in HER2-Mutated Solid Tumors
Zongertinib showed responses across HER2-mutated tumor types, including in lung cancer, with a tolerable safety profile.
FDA Approves Mirdametinib for NF1-Associated Plexiform Neurofibromas
The FDA has approved mirdametinib for patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas.
Precise Targets and Drug Sequencing Potential Characterize the State of ADCs in Ovarian Cancer
Kathleen N. Moore, MD, MS, discusses ongoing trials of novel ADCs in ovarian cancer and the potential relevance of biomarker expression for these agents.
Sotorasib Plus Panitumumab Provides Effective Targeted Therapy Option in KRAS G12C+ mCRC
Marwan G. Fakih, MD, discusses the FDA approval of sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.